{
    "organizations": [],
    "uuid": "a3f1db9a452ce75fc9a58ea3eefc6906687ebf2d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-says-comple/brief-eleven-biotherapeutics-says-completed-enrollment-for-late-stage-bladder-cancer-study-idUSASC09RPR",
    "ord_in_thread": 0,
    "title": "BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 10:35 AM / in 22 minutes BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study Reuters Staff March 12 (Reuters) - Eleven Biotherapeutics Inc: * ENROLLMENT COMPLETED IN PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER * ELEVEN BIOTHERAPEUTICS INC - ‍VISTA TRIAL OF VICINIUM IN NMIBC ON-TRACK FOR TOPLINE THREE-MONTH DATA IN MID-2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T12:34:00.000+02:00",
    "crawled": "2018-03-12T13:02:15.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "biotherapeutics",
        "say",
        "completed",
        "enrollment",
        "bladder",
        "cancer",
        "study",
        "reuters",
        "staff",
        "march",
        "reuters",
        "eleven",
        "biotherapeutics",
        "inc",
        "enrollment",
        "completed",
        "phase",
        "registration",
        "trial",
        "invasive",
        "bladder",
        "cancer",
        "eleven",
        "biotherapeutics",
        "inc",
        "trial",
        "vicinium",
        "nmibc",
        "topline",
        "data",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}